Trials / Terminated
TerminatedNCT03783403
A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
A Phase 1, Open-label, Dose Finding Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, Alone and in Combination With Cetuximab or Rituximab in Subjects With Advanced Solid and Hematologic Cancers
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 206 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, and preliminary clinical activity of CC-95251 as a single agent and in combination with cetuximab and rituximab in participants with advanced solid and hematologic cancers.
Detailed description
This is a test.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-95251 | Specified dose on specified days |
| DRUG | Rituximab | Specified dose on specified days |
| DRUG | Cetuximab | Specified dose on specified days |
Timeline
- Start date
- 2019-03-01
- Primary completion
- 2024-08-05
- Completion
- 2024-08-05
- First posted
- 2018-12-21
- Last updated
- 2024-09-19
Locations
31 sites across 7 countries: United States, Australia, Canada, France, South Korea, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03783403. Inclusion in this directory is not an endorsement.